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Summary
We have identified the first stop-codon point mutation
in mtDNA to be reported in association with human
disease. A 36-year-old woman experienced episodes of
encephalopathy accompanied by lactic acidemia and had
exercise intolerance and proximal myopathy. Histo-
chemical analysis showed that 90% of muscle fibers ex-
hibited decreased or absent cytochrome c oxidase (COX)
activity. Biochemical studies confirmed a severe isolated
reduction in COX activity. Muscle immunocytochem-
istry revealed a pattern suggestive of a primary mtDNA
defect in the COX-deficient fibers and was consistent
with either reduced stability or impaired assembly of the
holoenzyme. Sequence analysis of mtDNA identified a
novel heteroplasmic GrA point mutation at position
9952 in the patient’s skeletal muscle, which was not
detected in her leukocyte mtDNA or in that of 120
healthy controls or 60 additional patients with mito-
chondrial disease. This point mutation is located in the
3′ end of the gene for subunit III of COX and is predicted
to result in the loss of the last 13 amino acids of the
highly conserved C-terminal region of this subunit. It
was not detected in mtDNA extracted from leukocytes,
skeletal muscle, or myoblasts of the patient’s mother or
her two sons, indicating that this mutation is not ma-
ternally transmitted. Single-fiber PCR studies provided
direct evidence for an association between this pointmu-
tation and COX deficiency and indicated that the pro-
portion of mutant mtDNA required to induce COX de-
ficiency is lower than that reported for tRNA-gene point
mutations. The findings reported here represent only the
second case of isolated COX deficiency to be defined at
the molecular genetic level and reveal a new mutational
mechanism in mitochondrial disease.
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Introduction
A large number of primary defects of mtDNA have been
described in association with a group of human diseases
known as the mitochondrial myopathies and encephal-
omyopathies (Morgan-Hughes 1994). This is a group of
clinically and biochemically heterogeneous disorders
that frequently have the common feature of mitochon-
drial proliferation at the level of the single muscle fiber
(Morgan-Hughes 1994). The primary mtDNA defects
described fall broadly into two groups: large-scale re-
arrangements and point mutations (Holt et al. 1988;
Nelson et al. 1989; Moraes 1996; Schon et al. 1997).
Large-scale rearrangements, which include deletions and
duplications, are frequently associated with chronic pro-
gressive ophthalmoplegia, Pearson syndrome, and
Kearns-Sayre syndrome (Morgan-Hughes 1994; Poulton
et al. 1989). Point mutations may occur either in tRNA
genes or in structural genes. There are now 150 tRNA-
gene point mutations that have been described (Moraes
1996), the most common being at nucleotide positions
3243 and 8344, and these frequently are associated with
MELAS (mitochondrial encephalomyopathy with lactic
acidosis and strokelike episodes) syndrome andMERRF
(myoclonus epilepsy and ragged red fibers) syndrome,
respectively. Missense point mutations in protein-coding
genes are associated with Leber hereditary optic neu-
ropathy (Harding and Sweeney 1994). However, unlike
observations made in nuclear-genetic disorders, point
mutations leading to premature stop codons (null mu-
tations) in protein-coding genes have not been described
in human mtDNA. This is perhaps surprising, in view
of the high polymorphic rate of human mtDNA (Brown
et al. 1979). Point mutations are inherited in the ma-
trilineal line, whereas single deletions of mtDNA are
sporadic and are rarely, if ever, transmitted (Morgan-
Hughes 1994).
Cytochrome c oxidase (COX), complex IV of the res-
piratory chain, catalyzes the transfer of electrons from
reduced cytochrome c to molecular oxygen, forming wa-
ter, and has proton-pumping activity (Capaldi 1990). It
comprises 13 subunits, 3 encoded by mtDNA and the
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remainder encoded in the nucleus. Isolated complex IV
deficiency is not infrequently associated with pediatric
disorders such as subacute necrotizing encephalomye-
lopathy, fatal infantile myopathy, myopathy with car-
diomyopathy, and benign reversible COX deficiency
(DiMauro et al. 1994). These disorders generally de-
velop during the first few years of life and are thought
to be autosomal recessive, but, to date, no nuclear-gene
defect has been identified (Adams et al. 1997; Munaro
et al. 1997).
We now report an adult patient with recurrent en-
cephalopathy, myopathy, and exercise-induced myalgia
who had isolated COX deficiency demonstrated bio-
chemically and histochemically. A new stop-codon point
mutation in the COX III gene has been identified, and
we provide evidence that, uniquely, this point mutation
is not inherited in the matrilineal line.
Patients and Methods
Patients
The proband is a 36-year-old woman who was a nor-
mal full-term delivery and who had normal early motor
and cognitive development. She was good at sports at
school and excelled in middle-distance running. At the
age of 17 years she collapsed at the end of a 1.5-km race
and was found to be confused and complaining of a
headache. She recovered during the next few hours and
remained well for the next 4 years. In retrospect, this
may have been an episode of exercise-induced lactic ac-
idosis. At the age of 21 years she began to experience
symptoms of fatigue after exertion and, soon after ex-
ertion, would develop generalized muscle aches that
could last for X24 h but were not accompanied by pig-
menturia. She stopped drinking alcohol, which exacer-
bated her myalgia, gave up athletics, and became less
active. Her symptoms became much worse during her
three pregnancies, although her labors were uneventful.
At the age of 28 years, 3 mo after her third child was
born, she developed a marked increase in fatigue, with
headaches, over the course of 1 wk. She subsequently
became drowsy and confused and was admitted to hos-
pital in a stuporous state.
On clinical examination she had a reduced level of
consciousness. She exhibited decorticate posturing on
painful stimulation, but there was no spontaneousmove-
ment. There were roving eye movements. All four limbs
exhibited increased tone in a spastic fashion, and there
was generalized hyperreflexia with extensor-plantar re-
sponses. Laboratory investigations showed an increased
anion gap and metabolic acidosis that were due to an
elevated level of plasma lactate (7 mmol/liter). Serum
creatine kinase was elevated, at 860 IU (normal !150
IU/liter). An electroencephalogram showed widespread
slow-wave abnormalities, which resolved over the next
72 h. Results of both computed-tomography brain
scan on admission and subsequent magnetic-reso-
nance–imaging brain scans have been normal. She re-
covered from this episode but had two further identical
presentations over the next year. There was no evidence
of intercurrent illness preceding any of these episodes.
Since the age of 29 years her symptoms and signs have
been static. She experiences fatigue and myalgia and fre-
quent common migraine-type headaches. Current clin-
ical examination shows symmetrical proximal (mild)
muscle weakness involving all four limbs. Results of elec-
tromyogram and nerve conduction studies have been
normal. Exercise testing by a bicycle ergometer, as de-
scribed elsewhere (Petty et al. 1986), has demonstrated
an abnormal lactate response to sub–anaerobic-thresh-
old exercise, consistent with a defect in respiratory-chain
function. The patient has been unable to tolerate phos-
phorous magnetic-resonance spectroscopy (MRS) stud-
ies of her muscle or proton MRS of her brain.
Her mother had a hypertensive intracerebral hemor-
rhage at the age of 50 years, from which she recovered,
and she is otherwise well. The patient has three sons,
ages 16, 15, and 10 years. The youngest son is well. The
two older sons describe episodes of myalgia lasting X24
h that are not clearly related to exertion, but they have
normal muscle function and, indeed, are both good ath-
letes. The eldest son has a history of predominantly noc-
turnal episodes in which he becomes confused and de-
scribes vivid visual hallucinations. Despite extensive
investigation, no abnormality has been identified in these
two boys, and, in particular, there is no evidence of res-
piratory-chain dysfunction (see Results section). Our
current hypothesis is that these two sons are exhibiting
psychologically driven symptoms reinforced by their
mother’s illness behavior; they are currently undergoing
family therapy.
Methods
Histochemical and immunocytochemical analy-
sis.—Ten-micron cryostat sections of frozen muscle were
stained to demonstrate the activities of COX and suc-
cinate dehydrogenase (SDH). COX activity was deter-
mined in medium containing 4 mM 3,3′-diaminoben-
zamidine and 100 mM cytochrome c in 0.1 mM phos-
phate, pH 7.0, at 25C. SDH activity was determined
by 1.5 mM nitroblue tetrazolium, 130 mM sodium suc-
cinate, 0.2 mM phenazine methosulfate, and 0.1 mM
sodium azide in 0.1 mM phosphate, at pH 7.0 at 25C.
Sections were also stained with the Gomori trichrome
stain (Engel and Cunningham 1963).
A battery of subunit-specific mouse monoclonal an-
tibodies was used to identify COX subunits immunohis-
tochemically in serial muscle sections (Taanman et al.
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1996). The antibodies were directed against the follow-
ing subunits: I and II (mtDNA encoded) and IV, Va, and
VIc (nuclear-DNA encoded). Visualization was by the
Strept ABC technique, by use of 3,3′-diaminobenzidine
(Rahman et al. 1997).
Biochemical analysis.—Mitochondria were isolated
from skeletal muscle removed from the left quadriceps.
Polarographic determination of mitochondrial func-
tion, spectrophotometric analysis of respiratory-
chain–enzyme activities, and low-temperature analysis
of cytochrome content were performed as described else-
where (Morgan-Hughes et al. 1977; Mann et al. 1992).
mtDNA analysis.—Total DNA was extracted from
blood, muscle, skin, fibroblast, and myoblast cultures,
by standard techniques described elsewhere (Hanna et
al. 1995b). Southern blotting was performed on total
muscle DNA (Holt et al. 1988). Oligonucleotide primers
with M13 tails at the 5′ end were designed to amplify
all mitochondrial tRNA genes and all three mitochon-
drially encoded COX subunits (sequences of primers are
available, on request, from the authors). DNA extracted
from muscle was used for DNA sequencing. The PCR
products generated were cleaned by Centricon filters,
and both strands were sequenced by a Dye Primer Taq
cycle sequencing kit (Applied Biosystems [ABI]). The se-
quencing products were then separated on 10% poly-
acrylamide-urea gels in a 373A automated DNA
sequencer (ABI). The sequence data generated were an-
alyzed by Seq Ed software (ABI).
A mismatch PCR was designed to screen for the 9952
point mutation identified, in which a restriction site for
the endonuclease, DraI, was created in the presence of
the mutant mtDNA. The forward primer was light
strand (L) 9817–9836; and the reverse mismatch primer
was heavy strand (H) 9973–9944 ATG GAG ACA TAC
AGA AAT ATT (the mismatch nucleotide is underlined).
Conditions for the mismatch PCR were as follows: an
initial denaturing step at 94C for 3 min, followed by
30 cycles of the following: 92C for 30 s, 53C for 30
s, and 72C for 20 s. A final extension step of 72C for
10 min was used. After digestion with DraI, the frag-
ments were separated on a 3.2% agarose gel stainedwith
ethidium bromide and were visualized on a UV-light
box. The 157-bp product was digested into two frag-
ments—of 135 bp and 22 bp—in mutant mtDNA but
not in wild-type mtDNA.
An adaptation of the same mismatch PCR was used
to quantitate the proportion of mutant mtDNA in total
muscle and single fibers from the patient. Fluorescently
labeled deoxynucleotide was added prior to the last cycle
of the mismatch PCR, followed by digestion with DraI.
The products were then separated on a 6% nondena-
turing polyacryalmide gel on a 373A DNA sequencer
(ABI) and quantified by GENESCAN software (ABI).
Single-fiber PCR.—Single-fiber PCR was performed
according to methods described elsewhere (Sciacco et al.
1994; Moraes and Schon 1996). Thirty-micron trans-
verse muscle sections were prepared and were reacted
for COX. Freshly stained sections were immersed in
50% ethanol. COX-positive fibers and fibers with no
visually detectable COX activity were selected. Single-
fiber segments were removed by a borosilicate micro-
capillary tube under an inverted-light microscope. The
removed segments were put into 10 ml water and im-
mediately were centrifuged for 10 min. The water was
removed, and 5 ml lysis solution was added (200 mM
potassium hydroxide and 50 mMDTT). The fibers were
then incubated in this lysis solution for 1 h at 65C, and
then 5 ml neutralizing solution was added (900 mMTris-
HCl, pH 8.3, and 200 mM HCl). The fluorescent mis-
match PCR described above was then performed with
this 10-ml product.
Human myoblast and fibroblast culture.—Mass myo-
blast cultures were established from the diagnostic mus-
cle-biopsy sample, by methods described elsewhere
(Hanna et al. 1995a). Standard growth medium for
myoblasts comprised DMEM (Dulbecco’s modified Ea-
gle medium) with GLUTAMAX-1, 4.5 g glucose/liter,
110 mg sodium pyruvate/liter, 20% FCS, 2% detoxified
chick-embryo extract, 50mg uridine/ml, and 10mg gen-
tamycin/ml. Fibroblast cultures were established from
skin-punch biopsy samples, by the explant method
(Martin 1973). Growth medium for fibroblasts differed
from that used for myoblasts, in that 10% FCS was used
and chick-embryo extract was not used.
Results
Histochemical analysis of the patient’s muscle-biopsy
sample showed a marked reduction in COX activity, in
a mosaic distribution. Ten percent of the fibers exhibited
normal COX activity, whereas the remainder exhibited
reduced or absent activity (fig. 1). There were no ragged
red fibers, as determined by staining using the modified
Gomori trichrome method. Staining for SDH activity
revealed that !2% of the fibers exhibited a slightly in-
creased staining pattern, consistent with a mild degree
of mitochondrial proliferation. There were no SDH-in-
tense blood vessels. Biochemical analysis confirmed an
elevated citrate synthase activity in the muscle homo-
genate, compared with the control value, a result con-
sistent with some mitochondrial proliferation (table 1).
Results of histochemical analysis of the muscle-biopsy
samples from the patient’s two sons and from the pa-
tient’s mother were entirely normal. Immunocytochem-
ical studies using monoclonal antibodies directed against
both nuclear and mitochondrially encoded COX subun-
its were abnormal in the patient’s COX-negative fibers.
There was a selective reduction in staining with anti-
bodies against subunits I, II, and VIc. The staining pat-
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Figure 1 Muscle-biopsy serial sections from the proband,
stained for COX activity (A) and immunostained with antibodies di-
rected against subunits II (B), Va (C, and VIc (D). Panel A shows one
type I fiber (center) with normal COX activity (arrows). The remaining
fibers have markedly reduced COX staining. Fibers with reducedCOX
activity have reduced immunostaining with antibodies directed against
COX subunits II and VIc but have normal immunostaining with an-
tibodies directed against subunit Va. Fibers with reduced COX activity
also showed reduced immunostaining with antibodies directed against
subunit I and showed normal immunostaining with antibodies against
subunit IV (data not shown).
tern with antibodies directed against subunits IV and Va
did not differ from either that in normal controls or that
of COX-positive fibers in the patient’s biopsy sample
(fig. 1). Biochemical analysis of respiratory-chain en-
zymes in freshly isolated mitochondria of the patient
revealed a marked isolated decrease in both complex IV
activity (20% of the control value) and cytochrome aa3
content (17% of the control value) (table 1). Polaro-
graphic studies showed decreased oxygen consumption
with the natural substrates—pyruvate  malate, gluta-
mate  malate, and succinate—all of which require a
fully functional COX. Oxygen consumption with the
artificial substrate ascorbate and tetramethyl-p-pheny-
lenediamine dihydrochloride reduces cytochrome aa3 di-
rectly, therefore bypassing cytochrome a. Results of res-
piratory-chain–enzyme studies of the patient’s sons and
of her mother were normal (data not shown).
A large-scale rearrangement was excluded by South-
ern blotting. DNA sequence analysis of all 22 mito-
chondrial tRNA genes and of the genes for subunits I,
II, and III of COX was undertaken. Three changes were
identified, compared with the Anderson et al. (1981)
sequence; these were T14766C in the cytochrome b gene,
A1438G in the 12SrRNA gene, and G9952A in the gene
for subunit III of COX. The first two changes are rec-
ognized to be neutral polymorphisms (Kobayashi et al.
1990; Tanaka and Ozawa 1994). The GrA transition
at position 9952 has not been described elsewhere (fig.
2). This mutation results in the wild-type TGA codon
for tryptophan being converted into a TAA stop codon.
This premature stop codon is predicted to result in the
loss of the last 13 amino acids of the highly conserved
C-terminal region of subunit III of COX. This mutation
was heteroplasmic in the patient’s muscle but was not
detected in her skin or blood or in the blood or muscle
samples taken from her two sons and from her mother.
The G9952A mutation was not present in either 120
healthy control samples or 60 additional patients with
mitochondrial disease but with no known mtDNA mu-
tation. The proportion of mutant mtDNA was the same
(57%) in the patient’s muscle-biopsy samples in 1990
and in 1997. Early-passage myoblasts and fibroblasts
from the proband and myoblasts from her mother and
her two sons were grown in medium, to support res-
piratorily deficient cells, as described in the Methods
subsection. However, none of these cell lines harbored
the G9952A mutation.
Single-fiber PCR studies were performed to investigate
the relationship between the mutation identified and
COX deficiency at the level of the single muscle fiber.
The mean proportion of mutant mtDNA in the COX-
negative fibers ( ) was 56.2% (standard error ofn  24
the mean [SEM] 5.1%), and that in the COX-positive
fibers ( ) was 10.1% (SEM 2.3%) ( , byn  21 P ! .0002
t-test).
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Figure 2 Electropherograms showing wild-type G nucleotide at
position 9952 in control muscle mtDNA (top) andmutant A nucleotide
(asterisk [*]) in the proband’s muscle mtDNA (bottom).
Table 1
Biochemical Analyses in Isolated Muscle Mitochondria from the Proband
Probanda
Mean  SD
in Controls
( )n  5
Mitochondrial state–3 respiration rates for substrates (nmol O2/min/mg mitochondrial protein):
Pyruvate  malate 61 106 17.6
Glutamate  malate 54 107 25.6
Succinate  rotenone 79 147 49.6
Ascorbate TMPD 468 305 109.6
Respiratory-chain–enzyme activities:
Rotenone-sensitive NADH CoQ reductase (nmol/min/mg mitochondrial protein) 126 182 64
Succinate cytochrome c reductase (nmol/min/mg mitochondrial protein) 333 242 134
COX (1st-order rate constant/min/mg/mitochondrial protein) 7.66 44.4 14.6
Vmax (nmol/min/mg mitochondrial protein) using 50 mM cytochrome c 383 2,189 774
Citrate synthase:
nmol/min/mg mitochondrial protein 1,719 1,180 186
mmol/min/gm muscle homogenate 13.35 9.5 1.7
Cytochrome concentrations (nmol/mg mitochondrial protein):
b .494 .41 .09
c .646 .69 .10
c1 .486 .54 .07
aa3 .10 .42 .09
NOTE.—For methods, see Morgan-Hughes et al. (1977); Mann et al. (1992).
a Abnormal results are underlined.
Discussion
Isolated COX deficiency as observed in this case is
rare after the 1st decade of life, and there are few re-
ported. Haller et al. (1989) identified a 27-year-old
woman with life-long exercise intolerance and a mild
proximal limb weakness. A muscle-biopsy sample
showed no frank ragged red fibers by the Gomori tri-
chrome stain but did show that 190% of the fibers had
virtually absent COX activity. This defect was confirmed
spectophotometrically. There was no family history, and
no molecular-genetic data were reported. A recent case
reported by Keightley et al. (1996) is a 15-year-old fe-
male who experienced recurrent episodes of myoglobi-
nuria and muscle cramps with no muscle weakness on
examination. A muscle-biopsy sample in this patient did
show typical ragged red fibers and 64% COX-negative
fibers. Results of immunoblotting and immunocyto-
chemistry were consistent with either a lack of assembly
or instability of the COX holoenzyme. A heteroplasmic
in-frame 15-bp microdeletion was identified in the COX
III gene. Although the patient described by Haller et al.
had some clinical features in common with the patient
whom we have reported, neither of these cases had ev-
idence of CNS disease, which is the most likely cause of
our patient’s recurrent encephalopathy. Adult-onset
Leigh syndrome has been reported in association with
COX deficiency, but our patient does not have the im-
aging features seen in this condition (Adams et al. 1997).
COX deficiency in combination with other respiratory-
chain–complex deficiencies is much more commonly
seen in adults, and, in such cases, a primary defect in
mtDNA, resulting in impaired intramitochondrial pro-
tein synthesis, is frequently identified (Hanna et al.
1995b).
Immunocytochemical studies in our patient demon-
strated a decreased staining pattern in COX-negative
fibers, with antibodies directed against subunits I, II, and
VIc. The staining patterns with antibodies directed
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against subunits IV and Va did not differ from those in
controls. We have observed this pattern of immunos-
taining in COX-negative fibers in patients with a number
of primary defects of mtDNA (Rahman et al. 1997). In
contrast, different staining patterns are observed in
COX-negative fibers from patients in whom no mtDNA
defect has been identified and who are suspected to have
nuclear-gene mutations as the basis of their COX defi-
ciency (Rahman et al. 1997). The explanation for these
different immunostaining patterns remains to be deter-
mined. However, it is possible that primary mtDNA de-
fects that result in either impaired synthesis or altered
amino acid sequence of subunits may impair holoenzyme
assembly. This may render certain subunits more sus-
ceptible to degradation. Recent X-ray crystallographic
studies in bovine heart COX suggests that subunit VIc
is intimately related to subunit II, which may explain
why, in patients with primary mtDNA defects, the im-
munostaining pattern of this nuclear subunit mirrors the
other mtDNA-encoded COX components (Tsukihara et
al. 1996). It is possible that some of the normally syn-
thesized nuclear COX subunits in patients with primary
mtDNA defects may be able to associate into a subcom-
plex that is resistant to degradation.
In view of both the mosaic pattern of COX deficiency
and the pattern of immunostaining abnormalities de-
scribed, we have analyzed the muscle mtDNA in this
patient. Sequencing of all 22 tRNA genes and of the
genes for subunits I and II of COX showed two changes
from the published mtDNA sequence (Anderson et al.
1981), which are recognized polymorphisms (Kobayashi
et al. 1990; Tanaka and Ozawa 1994). However, se-
quence analysis of the gene for subunit III of COX
showed a GrA transition mutation at position 9952. In
keeping with previously described mtDNA mutations
associated with disease, there were two features that sug-
gested that this mutation was likely to be pathogenic.
First, it was heteroplasmic, a feature generally associated
with disease-associated mtDNA mutations rather than
with neutral polymorphisms. Second, it did not occur in
120 healthy control individuals. However, unlike any
other mtDNA point mutation described, this mutation
results in a premature stop codon being introduced at
the 3′ end of the COX III gene. This predicts the loss of
the final 13 amino acids of the COX III subunit. This
region of COX III has been highly conserved during
evolution, suggesting that it is likely to have functional
importance (Desjardin and Morais 1989). Within this
same region, a point mutation at position 9957, resulting
in an amino acid change, has been described in a patient
with MELAS, indicating that defects in this region may
associate with disease (Manfredi et al. 1995).
The mutant load in our patient’s most recent muscle
biopsy, performed in 1997, was 57%; that in an earlier
muscle biopsy, performed in 1990, was identical. This
is in contrast with observations made in relation to a
recently identified tRNA-gene point mutation, in which
increases in both mutant load and proportion of ragged
red fibers were documented over a 12-year period (We-
ber et al. 1997). Despite a severe decrease in COX ac-
tivity in our patient’s muscle, there wasminimal evidence
of mitochondrial proliferation, and, therefore, there
were no true ragged red fibers. The absence of true rag-
ged red fibers may, at least in part, account for the sta-
bility of the mutant load over 7 years. The precise cel-
lular trigger for mitochondrial proliferation remains
unknown. The case reported by Keightley et al. (1996),
which also harbored a mutation in the COX III gene,
did exhibit marked mitochondrial proliferation and rag-
ged red fibers, indicating that it is unlikely that COX
deficiency itself is the trigger for mitochondrial
proliferation.
To study the relationship between the 9952 mutation
and COX deficiency, we performed single-fiber PCR.We
observed a clear relationship between COX deficiency
and the proportion of mutant mtDNA, at the level of
the single fiber. The mean proportion of mutant mtDNA
in the 24 COX-negative fibers analyzed was 56.2%,
whereas that in 21 COX-positive fibers was 10.1% This
suggests that the threshold for expression of this mu-
tation is lower than that reported for other mtDNA
point mutations. For example, the threshold for ex-
pression of tRNA-gene point mutations is generally re-
ported to be 185%, although this may differ in different
cell types, possibly depending on mtDNA copy number
(Boulet et al. 1992; Chomyn et al. 1994; Hanna et al.
1995a). However, there is no a priori reason why the
behavior of this unique stop-codonmutation shouldmir-
ror the behavior of other, previously identified point mu-
tations. Indeed, our data suggest that the rules governing
the threshold for expression of this mutation are quite
different from those influencing the threshold for ex-
pression of tRNA-gene point mutations. The high
threshold for expression of mtDNA tRNA-gene point
mutations is thought to be due, at least in part, to in-
tramitchondrial complementation (Boulet et al. 1992).
It is possible that such complementation does not occur
for defective COX subunits. Alternatively, the lower
threshold may occur because functional COX is a dimer
(Tsukihara et al. 1996). At a mutant level of 50%, 75%
of COX holoproteins would be defective, and this may
be enough to produce the biochemical phenotype ob-
served. A functional threshold of 75% (i.e., 75% of a
COX subunit is defective) is similar to that observed in
some deletions of mtDNA (Hanna et al. 1998).
Although the C-terminal region of the COX III sub-
unit is highly conserved, its precise function is not
known. Indeed, the function of the entire COX III sub-
unit remains to be elucidated. It is now established that
it is not involved in the proton-pumping capability of
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COX, but there is some evidence, from studies in Par-
acoccus dentrificans, that it may have a role in either
energy conservation or assembly of the holoenzyme
(Haltia et al. 1991; Wu et al. 1995). We were unable to
study the consequences of this mutation in a cell-culture
system, since neither fibroblasts nor early-passagemyob-
lasts from the patient harbored any detectable mutation.
The absence of this mutation in early-passage myoblasts
may suggest that the mutation is in fact not present in
the satellite-cell population from which such myoblast
cultures are derived. This possibility has been suggested
in relation to another tRNA-gene mutation recently
identified (Weber et al. 1997), and it may have thera-
peutic implications (Clark et al. 1997; Shoubridge et al.
1997).
mtDNA has been shown to be virtually exclusively
maternally inherited, since the spermatozoon contributes
no mitochondria to the zygote (Giles et al. 1980). Pri-
mary mtDNA point mutations, as well as their associ-
ated diseases, have been shown to exhibit strict matri-
lineal inheritance. In contrast, deletions of mtDNA are
sporadic in the vast majority of cases, and matrilineal
inheritance is rarely observed (Larsson et al. 1992; Ber-
nes et al. 1993). The absence of this COX mutation in
any of the tissues examined in the maternal relatives
indicates that, in our patient, it probably arose as a spo-
radic event. The lack of transmission to her sons is sur-
prising and, in this respect, resembles the observations
described in relation to single deletions of mtDNA.
There are at least three ways in which the observed lack
of transmission may be explained: (1) the mutation may
not be present in the germ line; (2) it may be present in
very low amounts in oocytes and be filtered out by the
bottleneck thought to exist during oogenesis (Hauswirth
and Laipis 1985); or (3) it may be lost during either
oogenesis or early embryogenesis, possibly because of a
selective disadvantage of cells harboring high propor-
tions of the mutant molecule. Since germ-line tissues
from the proband are not available for study, it is not
possible to pursue this question.
In conclusion, we have identified the first stop-codon
mutation in human mtDNA and have provided evidence
that it is associated with adult-onset isolated COX de-
ficiency. This mutation is likely to induce COX defi-
ciency by a novel mechanism, possibly by affecting the
assembly of complex IV. This point mutation, in contrast
to others described, is not transmitted in the maternal
line.
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